XML 18 R8.htm IDEA: XBRL DOCUMENT

Development-Stage Risks and Liquidity	9 Months Ended
Development-Stage Risks and Liquidity	Sep. 30, 2023
Development-Stage Risks and Liquidity
Development-Stage Risks and Liquidity	Development-Stage Risks and Liquidity The Company has incurred losses since inception and has an accumulated deficit of $224.1 million as of September 30, 2023. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales from its product candidates currently in development. Management believes that cash, cash equivalents and marketable securities of $94.1 million as of September 30, 2023 are sufficient to sustain planned operations into the first quarter of 2025. The Company is subject to those risks associated with any specialty biotechnology company that has substantial expenditures for research and development. There can be no assurance that the Company’s research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants.